Allogene Therapeutics Doubles Authorized Shares, Activates $135M ATM Program

summarizeSummary

Allogene Therapeutics shareholders approved doubling authorized common stock to 800 million shares, and the company activated a $135 million At-The-Market (ATM) offering program, significantly increasing its capacity for future capital raises.

check_boxKey Events

• Authorized Shares Doubled

  Shareholders approved an amendment to increase authorized common stock from 400,000,000 to 800,000,000 shares. With 345,024,351 shares outstanding as of April 20, 2026, this authorizes the company to issue an additional 454,975,649 shares. If all authorized shares were issued, dilution would be 131.87%. This follows the PRE 14A and DEF 14A filings in April seeking this approval.

• $135 Million ATM Program Activated

  The company filed a prospectus supplement to sell up to $135.0 million of common stock through an At-The-Market (ATM) offering. This is an update to an existing program established November 5, 2019, and provides additional capital-raising flexibility following a $175 million offering in April.

• Routine Annual Meeting Approvals

  Shareholders also elected three Class II Directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent auditor for 2026. These are standard annual meeting items.

auto_awesomeAnalysis

Shareholders have approved a substantial increase in authorized shares, providing the company with the flexibility to issue up to 800 million shares. This, combined with the activation of a $135 million At-The-Market (ATM) program, indicates a proactive strategy to secure long-term funding. While this extends the company's financial runway, the significant potential for future dilution could weigh on existing shareholders.